- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03112343
Information and Communication Technology Based Centralized Clinical Trial Monitoring System for Insulin Dose Adjustment (ICT)
An Information and Communication Technology-based Centralized Clinical Trial to Determine the Efficacy and Safety of Insulin Dose Adjustment Education Based on a Smartphone Personal Health Record Application
This is a 24-week, open-label, randomized, multi-center trial conducted in three tertiary hospitals. There are three follow-up measures; at baseline, post-intervention at Week 12, and Week 24. Subjects are diagnosed as type 1 DM, type 2 DM, and/or post-transplant DM, and initiate or currently use insulin therapy. After the given education on insulin dose titration and prevention for hypoglycemia and 1 week of run-in period, subjects are randomized in a 1:1 ratio to either the ICT-based intervention group or the conventional intervention group. Subjects in conventional intervention group will save and send their health information to the server via the PHR app, whereas those in ICT-based intervention group have additional algorithm-based feedback messages. The health information includes levels of blood glucose, insulin dose, details on hypoglycemia, food diary, and number of steps. The primary outcome will be the proportion of patients who reach an optimal insulin dose within 12 weeks of enrolling in the study without severe hypoglycemia or unscheduled clinic visits.
This study is based upon work supported by the Ministry of Trade, Industry & Energy (MOTIE, Korea) under Industrial Technology Innovation Program (No. 10059066, 'Establishment of ICT Clinical Trial System and Foundation for Industrialization.")
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Seoul, Korea, Republikken, 135-710
- Samsung Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
- age between 18-69 years
- diagnosis of T1DM, T2DM, and/or post-transplant DM (Post-transplant DM includes both diagnosed T1DM or T2DM before organ transplantation and first diagnosed DM after organ transplantation)
- initiation or current use of insulin therapy including once-daily basal insulin (including basal insulin only or basal insulin plus rapid-acting insulin), premixed insulin, or NPH)
- most recent hemoglobin A1c (HbA1c) ≥7.0% based on the National Glycohemoglobin Standardization Program (NGSP) at least 3 months prior to participation (recent HbA1c values measured <3 months prior to screening are permitted.)
- available to use smartphone and wireless internet
- Voluntarily write consent to participate in the trial
Exclusion criteria
- on insulin pump
- history of alcohol or drug abuse 1 year prior to participation
- history of psychological disorder (e.g., schizophrenia, depression, or bipolar disorder)
- history of severe visual or hearing impairment
- pregnant
- any condition, in the investigator's opinion, not suitable for enrollment eligibility.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: ICT-based intervention
Subjects in the ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
|
ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
Subjects will save and send their health information to the server via the personal health record app
|
Placebo komparator: Conventional intervention group
Subjects in the conventional intervention group will only save and send their health information to the server via the personal health record app
|
Subjects will save and send their health information to the server via the personal health record app
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
the proportion of patients who reach his/her optimal insulin dose within 12 weeks of enrolling in the study without severe hypoglycemia or unscheduled clinic visits.
Tidsramme: Week 12
|
Reaching optimal insulin dose: A.For a patient who uses basal insulin only or basal insulin with pre-meal rapid-acting insulin once per day,1)3 or more fasting blood glucose(FBG) values in the morning within the target range(80-130mg/dL or 100-140 mg/dL) during Week12,2)no nocturnal(11pm-7am) or pre-breakfast hypoglycemia(<70mg/dL) during Week12,3)variation of basal insulin dose (the difference between the highest and lowest basal insulin dose) of <10% of mean total basal insulin dose during Week12.
B.For a patient who uses MDI at least twice per day, the criteria A plus 4)3 or more days in which correction dose premeal insulin is required less than 3times per day during the Week12,5) no daytime(7am-11pm) hypoglycemia during Week12.
C.For a patient who uses premixed insulin or NPH,1)3 or more FBG values in the morning and evening within the target range during Week 12,2) no nocturnal or pre-breakfast hypoglycemia during Week12
|
Week 12
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
the proportion of patients who reach HbA1c <7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 24
Tidsramme: Week 24
|
the proportion of patients who reach HbA1c <7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 24
|
Week 24
|
the proportion of patients who reach HbA1c <7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 12
Tidsramme: Week 12
|
the proportion of patients who reach HbA1c <7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 12
|
Week 12
|
mean fasting blood glucose values for three consecutive days prior to Week 12 and Week 24
Tidsramme: Week 12 and 24
|
mean fasting blood glucose values for three consecutive days prior to Week 12 and Week 24
|
Week 12 and 24
|
levels of HbA1c at Week 12 and Week 24
Tidsramme: Week 12 and Week 24
|
levels of HbA1c at Week 12 and Week 24
|
Week 12 and Week 24
|
lipid profile at Week 12 and Week 24
Tidsramme: Week 12 and 24
|
lipid profile at Week 12 and Week 24
|
Week 12 and 24
|
the proportion of patients having hypoglycemia (total, asymptomatic, daytime, nighttime, severe hypoglycemia, and coma/convulsions) at Week 12 and Week 24
Tidsramme: Week 12 and Week 24
|
the proportion of patients having hypoglycemia (total, asymptomatic, daytime, nighttime, severe hypoglycemia, and coma/convulsions) at Week 12 and Week 24
|
Week 12 and Week 24
|
the number of steps during Week 1-12 and Week 13-24
Tidsramme: Week 12 and Week 24
|
the number of steps during Week 1-12 and Week 13-24
|
Week 12 and Week 24
|
recorded exchange unit by food group
Tidsramme: Week 12 and 24
|
recorded exchange unit by food group (grains, meats and protein, fruits, vegetables, dairy, and fats and oils) in each breakfast, lunch, and dinner on 3-day food diary at Week 12 and 24
|
Week 12 and 24
|
daily insulin dose
Tidsramme: Week 12 and Week 24
|
daily insulin dose at Week 12 and Week 24
|
Week 12 and Week 24
|
blood pressure
Tidsramme: Week 12 and Week 24
|
blood pressure at Week 12 and Week 24
|
Week 12 and Week 24
|
body weight
Tidsramme: Week 12 and Week 24
|
body weight at Week 12 and Week 24
|
Week 12 and Week 24
|
lean body mass
Tidsramme: Week 12 and 24
|
lean body mass at Week 12 and Week 24
|
Week 12 and 24
|
fat mass
Tidsramme: Week 12 and 24
|
fat mass at Week 12 and Week 24
|
Week 12 and 24
|
Satisfaction evaluation by questionnaire for ICT-based centralized clinical trial monitoring
Tidsramme: Week 12 and 24
|
Satisfaction evaluation by questionnaire for ICT-based centralized clinical trial monitoring at Week 12 and 24
|
Week 12 and 24
|
Satisfaction evaluation by DTSQ
Tidsramme: Week 12 and 24
|
Satisfaction evaluation by DTSQ at Week 12 and 24
|
Week 12 and 24
|
the number of telephone counselling by diabetes educators
Tidsramme: Week 12 and 24
|
the number of telephone counselling by diabetes educators
|
Week 12 and 24
|
the number of self-monitoring blood glucose measurements
Tidsramme: Week 12 and 24
|
the number of self-monitoring blood glucose measurements
|
Week 12 and 24
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studiestol: Sang-Man Jin, MD PhD, Samsung Medical Center
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2016-08-006-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus
-
Medical College of WisconsinMedical University of South CarolinaAfsluttetDiabetes mellitus | Type 2 diabetes mellitus | Voksen-debuterende diabetes mellitus | Ikke-insulinafhængig diabetes mellitus | Ikke-insulinafhængig diabetes mellitus, type IIForenede Stater
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinafhængig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | Diabetes mellitus, skør | Diabetes Mellitus... og andre forholdForenede Stater
-
SanofiAfsluttetType 1-diabetes mellitus-type 2-diabetes mellitusUngarn, Den Russiske Føderation, Tyskland, Polen, Japan, Forenede Stater, Finland
-
Meir Medical CenterAfsluttetDiabetes mellitus type 2 | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, om oral hypoglykæmisk behandling | Voksen type diabetes mellitusIsrael
-
Peking Union Medical College HospitalUkendtType 2 diabetes mellitus | Type 1 diabetes mellitus | Svangerskabsdiabetes mellitus | Pancreatogen diabetes mellitus | Prægestationsdiabetes mellitus | Diabetespatienter i perioperativ periodeKina
-
Guang NingRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitus | Monogenetisk diabetes | Pancreatogen diabetes | Lægemiddel-induceret diabetes mellitus | Andre former for diabetes mellitusKina
-
Hoffmann-La RocheRoche DiagnosticsAfsluttetDiabetes mellitus type 2, diabetes mellitus type 1Tyskland
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and...Aktiv, ikke rekrutterendeDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
Kliniske forsøg med Algorithm-based feedback messages
-
Universidad Pública de NavarraMutua NavarraUkendtSkulderpåvirkning | Rotator Cuff sygdomSpanien